Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coya Therapeutics, Inc.COYA · Entity 6727 | Director | January 02, 2026 | January 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coya Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2036-01-02 | Direct | 10,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 10,000 · Balance 10,000 F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 7, 2026 00:27 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001193125-26-005024 · ownership.xml · derivative · entry 1 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock, par value $0.0001 per share · 10,000 shares Expires 2036-01-02 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 02:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0000950170-25-027254 · ownership.xml · derivative · entry 1 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2035-02-25 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| January 01, 2025 Filed Jan 4, 2025 02:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.73 | $0.00 |
DisclosureSEC source: 0000950170-25-001568 · ownership.xml · derivative · entry 1 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| January 01, 2024 Filed Jan 19, 2024 23:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001493152-24-003107 · ownership.xml · derivative · entry 1 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 13:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseWarrant to Purchase Common Stock · Derivative | 5,000 | Not disclosed Strike: $7.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-000222 · ownership.xml · derivative · entry 2 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires 2025-01-03 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 13:30 UTC | Coya Therapeutics, Inc. COYA · Entity 6727 | PurchaseCommon Stock, par value $0.0001 per share | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-000222 · ownership.xml · nonDerivative · entry 1 Villalobos Anabella · CIK 0001952966 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: Reporting Person purchased 10,000 shares of Common Stock and an accompanying warrant to purchase 5,000 shares of Common Stock in the Issuer's initial public offering at a combined purchase price of $5.00 per share and accompanying warrant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.